Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada Title Grant Type Focus Area Country Application Due Date Improvement of Treatment Environment for Advanced / Recurrent Breast CancerRelease Date:Education Oncology Japan Improving RCC Patient OutcomesRelease Date:Education Oncology France, Germany, Italy, Spain, USA, United Kingdom Biomarker Testing / Lung CancerRelease Date:Education Oncology Japan Employment support / Lung CancerRelease Date:Education Oncology Japan Immunotherapy in Urothelial CarcinomaEducation Oncology All PARP-inhibitor Combination Treatments in Prostate CancerRelease Date:Education Oncology USA Establishment of Hospital-Clinic Collaboration Model for Undiagnosed Rheumatic DiseasesRelease Date:Partner: The Japan College of RheumatologyQuality Improvement Inflammation & Immunology Japan Pre-clinical and Translational Research in Multiple MyelomaRelease Date:Research Oncology Italy Knowledge Gaps in Updated Adult Pneumococcal Immunization RecommendationsRelease Date:Education Vaccines USA COVID-19 Vaccine Development for LMICsRelease Date:Research Vaccines All Closing Knowledge Gaps in Transthyretin Cardiomyopathy (ATTR-CM)Release Date:Education Rare Disease USA Quality Improvement Grants to Support Development of Cardiac Amyloid CentersRelease Date:Quality Improvement Rare Disease USA